RYE, N.Y., Aug. 16 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company will present at the Rodman & Renshaw Annual Global Investment Conference, scheduled for September 12-15 at the New York Palace Hotel in New York City.
Dr. Joan Fallon, Curemark's founder and CEO, will update investors on the progress of the company's clinical research for CM-AT, its autism treatment in development. She will also discuss the Investigational New Drug (IND) authorization Curemark recently received from the FDA for CM – 4612 to treat attention deficit hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial for the use of CM – 4612 in the treatment of attention deficit hyperactivity disorder (ADHD).
"We are very happy to have this opportunity to present at the Rodman & Renshaw annual investment conference. Curemark has achieved a variety of major milestones that we are looking forward to sharing with attendees," Fallon said.
CM-AT, Curemark's autism treatment, addresses enzyme deficiencies in autistic children which affect the availability of amino acids, the building blocks of chemicals essential for brain function. Phase III clinical trials are underway at 13 sites nationwide for CM-AT, which has received Fast Track status from the FDA. If approved, it will be one of the first therapies to address the underlying physiology of autism.
Curemark's presentation is part of the 12th annual healthcare conference, an industry track that will be showcased during the Rodman & Renshaw Annual Global Investment Conference
|SOURCE Curemark, LLC|
Copyright©2010 PR Newswire.
All rights reserved